- Home
- XPER vs SIGA Comparison
XPER vs SIGA Comparison
Compare XPER & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPER
- SIGA
- Stock Information
- Founded
- XPER 1990
- SIGA 1995
- Country
- XPER United States
- SIGA United States
- Employees
- XPER N/A
- SIGA N/A
- Industry
- XPER Semiconductors
- SIGA Biotechnology: Pharmaceutical Preparations
- Sector
- XPER Technology
- SIGA Health Care
- Exchange
- XPER Nasdaq
- SIGA Nasdaq
- Market Cap
- XPER 463.5M
- SIGA 443.4M
- IPO Year
- XPER 2003
- SIGA 1997
- Fundamental
- Price
- XPER $9.00
- SIGA $6.23
- Analyst Decision
- XPER Strong Buy
- SIGA
- Analyst Count
- XPER 3
- SIGA 0
- Target Price
- XPER $19.00
- SIGA N/A
- AVG Volume (30 Days)
- XPER 318.5K
- SIGA 422.2K
- Earning Date
- XPER 02-26-2025
- SIGA 03-11-2025
- Dividend Yield
- XPER N/A
- SIGA 9.64%
- EPS Growth
- XPER N/A
- SIGA N/A
- EPS
- XPER N/A
- SIGA 1.20
- Revenue
- XPER $508,559,000.00
- SIGA $173,731,386.00
- Revenue This Year
- XPER N/A
- SIGA $16.79
- Revenue Next Year
- XPER $2.28
- SIGA $15.08
- P/E Ratio
- XPER N/A
- SIGA $5.21
- Revenue Growth
- XPER N/A
- SIGA 399.31
- 52 Week Low
- XPER $6.89
- SIGA $4.26
- 52 Week High
- XPER $12.29
- SIGA $12.83
- Technical
- Relative Strength Index (RSI)
- XPER 35.66
- SIGA 48.10
- Support Level
- XPER $8.82
- SIGA $6.16
- Resistance Level
- XPER $9.22
- SIGA $6.58
- Average True Range (ATR)
- XPER 0.32
- SIGA 0.26
- MACD
- XPER -0.18
- SIGA 0.04
- Stochastic Oscillator
- XPER 10.00
- SIGA 57.23
About XPER Xperi Inc.
Xperi Inc consumer and entertainment technology company. Its offering comprises a portfolio of software and services. Its business is divided into four categories based on the products delivered and customers served: Pay-TV, Consumer Electronics, Connected Car, and Platform Solutions. It generates the majority of its revenue from the Consumer Electronics segment.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.